Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary

Pediatric Pulmonology

Volumn 48, Issue 6, 2013, Pages 525-537

  Zobell, Jeffery T ^a,b   Young, David C ^c,d   Waters, C Dustin ^e   Ampofo, Krow ^f   Stockmann, Chris ^f   Sherwin, Catherine M T ^f   Spigarelli, Michael G ^f  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Pediatric Center   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Intermountain Cystic Fibrosis Adult Center   (United States)

^e McKay Dee Hospital Center   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

pharmacodynamics; pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DORIPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TIMENTIN; TOBRAMYCIN;

ACUTE PULMONARY EXACERBATION; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG UTILIZATION; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SURVEY; HEALTH CENTER; HUMAN; LUNG DISEASE; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE; UNITED STATES;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; EUROPE; GUIDELINE ADHERENCE; HUMANS; INJECTIONS, INTRAVENOUS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 84878313752     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22757     Document Type: Article

References (83)

1. Ramsey BW,. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-188. (Pubitemid 26249456)
2. Gibson RL, Burns JL, Ramsey BW,. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-951. (Pubitemid 37267172)
3. McCool FD, Rosen MJ,. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 250S-259S. (Pubitemid 43265229)
4. Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC,. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54: 522-537.
5. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642. (Pubitemid 24276863)
6. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PTP,. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240. (Pubitemid 43113028)
7. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30. (Pubitemid 29024680)
8. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oemann CM, McCoy KS, Montgomery AB, Cooper PJ,. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-1232.
9. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW,. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756. (Pubitemid 37430625)
10. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-1012. (Pubitemid 41476538)
11. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969. (Pubitemid 350127838)
12. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
13. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
14. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
15. Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 2012 (in press).
16. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatr Pulmonol 2013; 48: 1-7.
17. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CMT, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides. Pediatr Pulmonol 2012; in press
18. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ,. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
19. Trust UCF. Antibiotic treatment for cystic fibrosis in UK Cystic Fibrosis Trust Antibiotic Working Group. 2009.
20. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL,. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-370.
21. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
22. Sanders DB, Bittner RC, Rosenfeld M, Redding, GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
23. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
24. Parkins MD, Rendall JC, Elborn JS,. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012; 141: 485-493.
25. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V,. et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
26. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
27. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
28. Prescott WA, Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
29. Moore RD, Lietman PS, Smith CR,. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99. (Pubitemid 17225088)
30. Chambers HF,. Antimicrobial agents: The aminoglycosides. In:, Limbird JGHaLE, editor. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 1219-1238.
31. Foundation CF,. Microbiology and infectious disease in cystic fibrosis in Cystic Fibrosis Foundation Consensus Conference. 1994.
32. Zobell JT, Young DC, Chatfield BA,. Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis. Pediatr Pulmonol 2012 (in press).
33. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A,. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-578. (Pubitemid 40247913)
34. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA,. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16: 112-117; discussion 123-126. (Pubitemid 27063129)
35. Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA,. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010; 9: 280-283.
36. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
37. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL,. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101-109.
38. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R,. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989; 8: 858-865. (Pubitemid 19265870)
39. Salh B, Bilton D, Dodd M, Abbot J, Webb K,. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992; 24: 215-218.
40. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M,. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7: 142-146. (Pubitemid 351372759)
41. Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346. (Pubitemid 41507577)
42. Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR, Jullien V,. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy 2010; 30: 1252-1258.
43. Rey E, Treluyer JM, Pons G,. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-329. (Pubitemid 28491216)
44. Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ,. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238-243.
45. Prandota J,. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987; 6: 1111-1126. (Pubitemid 18029589)
46. de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL,. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990; 47: 73-78. (Pubitemid 20041213)
47. Sorgel F, Stephan U, Wiesemann HG, Gottschalk B, Stehr C, Rey M, Bowing HB, Dominick HC, Geldmacher von Mallinckrodt M,. High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection 1987; 15: 385-396. (Pubitemid 17156117)
48. Touw DJ,. Clinical pharmacokinetics, of antimicrobial, drugs in, cystic fibrosis. Pharm World Sci 1998; 20: 149-160. (Pubitemid 28393870)
49. Touw DJ, Vinks AA, Mouton JW, Horrevorts, AM,. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet 1998; 35: 437-459. (Pubitemid 29010175)
50. Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB,. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40: 29-34. (Pubitemid 26019673)
51. Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J,. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros 2007; 6: 125-130. (Pubitemid 46381653)
52. Tod MM, Padoin C, Petitjean O,. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001; 40: 803-814. (Pubitemid 33095997)
53. Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007; 81: 213-221. (Pubitemid 46174818)
54. Atkinson AJ, Jr., Lalonde RL,. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007; 82: 3-6. (Pubitemid 46944206)
55. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa, LJ, et al. Model-based drug development. Clin Pharmacol Ther 2007; 82: 21-32. (Pubitemid 46950619)
56. Peck CC, Cross JT,. " Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 2007; 82: 12-14.
57. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL,. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-607. (Pubitemid 40691835)
58. Mouton JW, Vinks AA,. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-210. (Pubitemid 40188941)
59. FAO/WHO/OIE. 2008. Joint FAO/WHO/OIE Expert Meeting on Critically Important Antimicrobials. Report of a meeting held in FAO, Rome, Italy, 26-30 November 2007. FAO, Rome, Italy, and WHO, Geneva, Switzerland.
60. Testing, E.C.o.A.S., Setting breakpoints for existing antimicrobial agents, EUCAST SOP 2.0, 2010; http://www.eucast.org.
61. Testing, E.C.o.A.S., Breakpoint tables for interpretation of MICs and zone diameters, 2011; EUCAST.
62. Institute, C.a.L.S., Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First International Supplement M 100-S21, 2011; CLSI: Wayne, PA.
63. Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
64. Burgess DS,. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99-S104. (Pubitemid 40270207)
65. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ,. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19: 1252-1260.
66. Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW,. Role for dual individualization with cefmenoxime. Am J Med 1984; 77: 43-50. (Pubitemid 15153297)
67. Azactam® Approved Package labeling, 2010, Bristol Meyers Squibb.
68. Doribax® Approved Package labeling, 2009, Ortho McNeil Janssen.
69. Prince AS, Neu HC,. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980; 97: 148-151. (Pubitemid 10033787)
70. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, Halsey NA,. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988; 4: 201-204.
71. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F,. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-2507. (Pubitemid 47047329)
72. Zosyn® Approved Package labeling, 2009, Wyeth.
73. Timentin® Approved Package labeling, 2010, GlaxoSmitKline.
74. Cipro® Approved Package labeling, 2008, Bayer.
75. Colistimethate sodium approved package labeling, 2010, X-Gen Pharmaceuticals.
76. Fortaz® Approved Package labeling., 2010, GlaxoSmithKline.
77. Maxipime® Approved Package lableling, 2009, Bristol Meyers Squibb.
78. Primaxin® Approved Package labeling, 2009, Merck.
79. Merrem® Approved Package labeling, 2009, AstraZeneca.
80. Amikacin sulfate approved package labeling, 2007, Bedford Laboratories.
81. Gentamicin sulfate approved package labeling, 2007, Braun Medical Inc.
82. Tobramycin sulfate approved package labeling, 2008, APP Pharmaceuticals, LC.
83. Levaquin® Approved Package labeling, 2011, Ortho-McNeil-Janssen Pharmaceuticals, Inc.